This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Artru, A. A. Articles by Michenfelder, J. D. Search for Related Content PubMed PubMed Citation Articles by Artru, A. A. Articles by Michenfelder, J. D.

Stroke, Vol 11, 197-199, Copyright © 1980 by American Heart Association

ARTICLES

A re-examination of physostigmine-induced cerebral protection in the hypoxic mouse. A critical assessment of the model

AA Artru and JD Michenfelder

Using the hypoxic (FiO2 = 0.05) mouse model as originally described, the survival time following pretreatment with physostigmine was examined. The maximum increase in survival time was 87% following a physostigmine dose of 0.4 mg/kg. This increase was considerably less than that previously reported for this drug in a hypoxic mouse study wherein the standard method for exposing mice to hypoxia was altered. We speculate that this alteration in methodology resulted in small variations in FiO2 sufficient to account for the differences between these studies.

This article has been cited by other articles:

				A. Bekker, M. Haile, K. Gingrich, L. Wenning, A. Gorny, D. Quartermain, and T. Blanck Physostigmine Reverses Cognitive Dysfunction Caused by Moderate Hypoxia in Adult Mice Anesth. Analg., September 1, 2007; 105(3): 739 - 743. [Abstract] [Full Text] [PDF]